ClinicalTrials.gg
CompletedNCT03308799Updated Dec 9, 2024Results posted

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

A Phase 3 interventional study of MC2-01 cream and Cal/BDP combination in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by MC2 Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
794
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
7th of 47
794 · median 200
Started
2017
with 4 others
Phase 3
17 of 47
none open now
Registered
33rd of 47
by date
Lead sponsor
4 of 47
MC2 Therapeutics

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 7th largest by enrollment, is one of 5 that started in 2017, is one of 17 in phase 3, and was the 33rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.

Read the detailed description

The MC2-01 Cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines. In this trial, the MC2-01 cream will be compared to a marketed product CAL/BDP combination and vehicle. The purpose of the trial is to compare the clinical efficacy, safety, and convenience of this cream to the marketed product. The trial will include a 8-week treatment period.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided written
  • Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening
  • Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration that involves the trunk and/or limbs that is amenable to topical treatment with a maximum of 100 g of trial medication per week
  • Have a PGA of disease severity of mild or moderate on the body (trunk and/or limbs)
  • An mPASI score of at least 2
  • Have a treatment area involving 2- 30% of the body surface area (BSA)

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of unstable forms of psoriasis
  • Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis vulgaris
  • Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
  • Planned exposure to either natural or artificial sunlight
  • History of to any component of the test product or reference product
  • Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
  • Systemic treatment with biological therapies
  • Use of systemic treatments that suppress the immune system and other systemic chemotherapeutic antineoplastic therapy within 4 weeks prior to the baseline visit and during the trial
  • Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial;
  • Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline
  • Clinical signs of skin infection with bacteria, viruses, or fungi
  • Known (HIV) infection
  • Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
794 participants (actual)

Study arms

  • Experimental
    MC2-01 Cream

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks

    Drug: MC2-01 cream

  • Active comparator
    Cal/BDP combination

    Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.

    Drug: Cal/BDP combination

  • Placebo comparator
    Cream vehicle

    One application daily for 8 weeks.

    Drug: Cream vehicle

Interventions

  • DrugMC2-01 cream

    Drug pages: Calcipotriene · Betamethasone dipropionate

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

  • DrugCal/BDP combination

    calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

  • DrugCream vehicle

    Vehicle Cream

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8

    Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening. The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Percentage Change in mPASI Score

    The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement. The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe. The mPASI score is calculated from the individual scores by use of the following equation: Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8. The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100

    Time frame: Baseline and 8 weeks

  2. Psoriasis Treatment Convenience Scale

    Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10. How easy was the treatment to apply to the skin? "Very difficult" is 1 and "Very easy" is 10 How greasy was the treatment when applying it to the skin? "Very greasy" is 1 and "Not greasy" is 10 How moisturised did your skin feel after applying the treatment? "Not moisturized" is 1 and "Very moisturized" is 10 How greasy did your skin feel after applying the treatment? "Very greasy" is 1 and "Not greasy" is 10 How much did treating your skin disrupt your daily routine? "Very disturbing" is 1 and "Not disturbing" is 10

    Time frame: 8 weeks

07

Results

Posted Oct 29, 2019

Participant flow

First Subject First Visit: 03-Oct-2017. Last Subject Last Visit: 08-Jun-2018.

Participant flow — Overall Study
MilestoneMC2-01 CreamCAL/BDP CombinationVehicle
Started342337115
Completed32030994
Not completed222821

Outcome measures

PrimaryNumber of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8

Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening. The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.

Time frame:
Baseline and 8 weeks
Reported as:
Number · Count of participants
Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8
Count of participantsMC2-01 CreamCAL/BDP CombinationVehicle
Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8121674
SecondaryPercentage Change in mPASI Score

The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement. The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe. The mPASI score is calculated from the individual scores by use of the following equation: Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8. The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100

Time frame:
Baseline and 8 weeks
Reported as:
Mean · Percentage of change
Percentage Change in mPASI Score
Percentage of changeMC2-01 CreamCAL/BDP CombinationVehicle
Percentage Change in mPASI Score64.8 ± 28.752.3 ± 33.325.7 ± 35.3
SecondaryPsoriasis Treatment Convenience Scale

Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10. How easy was the treatment to apply to the skin? "Very difficult" is 1 and "Very easy" is 10 How greasy was the treatment when applying it to the skin? "Very greasy" is 1 and "Not greasy" is 10 How moisturised did your skin feel after applying the treatment? "Not moisturized" is 1 and "Very moisturized" is 10 How greasy did your skin feel after applying the treatment? "Very greasy" is 1 and "Not greasy" is 10 How much did treating your skin disrupt your daily routine? "Very disturbing" is 1 and "Not disturbing" is 10

Time frame:
8 weeks
Reported as:
Mean · score on a scale
Psoriasis Treatment Convenience Scale
score on a scaleMC2-01 CreamCAL/BDP CombinationVehicle
Psoriasis Treatment Convenience Scale41.6 ± 6.637.8 ± 7.637.2 ± 7.1

Adverse events

Collected over AEs were collected/assessed during the screening period (up to 4 weeks) and during the 8 weeks treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MC2-01 Cream1/342 (0.3%)9/342 (2.6%)0/342 (0%)
CAL/BDP Combination0/337 (0%)11/337 (3.3%)0/337 (0%)
Vehicle1/115 (0.9%)5/115 (4.3%)0/115 (0%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventMC2-01 CreamCAL/BDP CombinationVehicle
Myocardial InfarctionCardiac disorders1/3420/3371/115
Application site cellulitisSkin and subcutaneous tissue disorders0/3421/3371/115
CholecystitisGastrointestinal disorders0/3420/3371/115
Ischaemic strokeCardiac disorders0/3420/3371/115
DeathCardiac disorders0/3420/3371/115
AbscessSkin and subcutaneous tissue disorders1/3421/3370/115
Angina PectorisCardiac disorders1/3421/3370/115
PneumoniaInfections and infestations1/3421/3370/115
DehydrationMetabolism and nutrition disorders0/3421/3370/115
PyrexiaInfections and infestations0/3421/3370/115

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MC2-01 CreamCAL/BDP CombinationVehicleTotal
Mean52.0 ± 14.452.6 ± 13.750.4 ± 14.352.0 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)MC2-01 CreamCAL/BDP CombinationVehicleTotal
Female13911644299
Male20322171495
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MC2-01 CreamCAL/BDP CombinationVehicleTotal
Race — White290299102691
Race — Black or African American34201165
Race — Asian1010121
Race — American Indian or Alaska Native3317
Race — Native Hawaiian or Other Pacific Islander2103
Race — Mutiple2305
Race — Other1102
Region of Enrollment
Region of Enrollment(participants)MC2-01 CreamCAL/BDP CombinationVehicleTotal
United States342337115794
Baseline PGA
Baseline PGA(Participants)MC2-01 CreamCAL/BDP CombinationVehicleTotal
Mild psoriasis685720145
Moderate psoriasis27428095649
Baseline mPASI
Baseline mPASI(Calculated score)MC2-01 CreamCAL/BDP CombinationVehicleTotal
Mean7.3 ± 3.97.7 ± 4.17.1 ± 4.17.4 ± 4.0
Baseline BSA
Baseline BSA(Percentage)MC2-01 CreamCAL/BDP CombinationVehicleTotal
Mean7.3 ± 6.08.4 ± 7.07.5 ± 6.17.8 ± 6.5
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)MC2-01 CreamCAL/BDP CombinationVehicleTotal
I2121951
II868830204
III10411237253
IV877323183
V3028967
VI1415736
08

Study locations

3 sites
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Richard Herdener, MD
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Feldman SR, Praestegaard M, Andreasen AH, Selmer J, Holm-Larsen T. Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS). Dermatol Ther (Heidelb). 2021 Dec;11(6):2077-2088. doi: 10.1007/s13555-021-00626-5. Epub 2021 Oct 14. PubMed 34648147 ↗
  • Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream. J Drugs Dermatol. 2021 Apr 1;20(4):420-425. doi: 10.36849/JDD.2021.5653. PubMed 33852251 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2018, 8 months.

Results were first posted in Oct 2019, 1 year 4 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2017
First posted
Oct 13, 2017
StartActual
Oct 3, 2017
Primary completionActual
Jun 8, 2018
CompletionActual
Jun 8, 2018
Results first posted
Oct 29, 2019
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03308799
Lead sponsor
MC2 Therapeutics
Responsible party
Sponsor
First posted
Oct 13, 2017
Start date
Oct 3, 2017
Primary completion
Jun 8, 2018
Completion
Jun 8, 2018
Results posted
Oct 29, 2019
Last update
Dec 9, 2024

Study contacts

Linda S. Gold, MD
principal investigator · Henry Ford Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion